Albuferon ACHIEVE-1 Study Shows Non-Inferiority To Pegasys, But That Fails To Convince

Final Phase III study of Human Genome Sciences/Novartis' hepatitis C drug meets primary endpoint, but Pegasys does better numerically, leading to poor reception on the Street.